復旦微電(688385.SH):上半年淨利潤同比預減39.67%至48.29%
格隆匯7月29日丨復旦微電(688385.SH)公佈2025年半年度業績預告,預計營業收入約爲人民幣18.2億元至18.5億元,同比增加1.44%至3.12%;預計實現歸屬於母公司所有者的淨利潤約爲人民幣1.8億元至2.1億元,同比減少39.67%至48.29%;預計歸屬於母公司所有者的扣除非經常性損益的淨利潤約爲人民幣1.7億元至2億元,同比減少35.24%至44.95%。
報告期內,公司各產品線所面對的市場競爭激烈,公司積極拓展新產品和新市場,鞏固或擴大市場佔有率。除非揮發存儲器外,集成電路設計板塊各產品線均取得增長,致營業收入有所提升;綜合毛利率水平同比基本穩定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.